IO Biotech Announces Publication of Five-year Clinical Outcomes of Phase 1/2 Trial in Nature Communications
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer
Blue Jay Gold Corp. Announces Engagement of Oak Hill Financial Inc. for Investor Relations and Retention of Haywood Securities for Market Making Services
QIMC Highlights Technical Advisory Role on First Atlas Matane Natural Hydrogen Project Following Quebec Parliamentary Committee Appearance
